Abeona Shares Higher After Pricing Stock Offering -- Biotech Movers

The clinical-stage biopharmaceutical firm said Oct. 16 it has priced an underwritten public offering of five million shares at $16 apiece.
Stocks quotes in this article: ABEO, ARDX, INSY

Shares of Abeona Therapeutics Inc. (ABEO) rose 1.8% to $17 in premarket trading on Tuesday, Oct. 17, after the company priced an underwritten public offering of five million shares at $16 apiece, which would generate gross proceeds of $80 million. Abeona has also given underwriters a 30-day option to buy up to an additional 750,000 shares.

Abeona said it plans to use the net proceeds for working capital and corporate purposes.

Meanwhile, shares of Ardelyx Inc. (ARDX) were up 4.6% to $6.70 after closing at $6.40 on Monday, down 12%.

The Fremont, Calif.-based firm on Monday morning said data from preclinical studies have shown that "tenapanor works to reduce abdominal pain caused by irritable bowel syndrome with constipation (IBS-C) through the inhibition of TRPV-1 dependent signaling."

Among the other biotech stock movers was Insys Therapeutics Inc. (INSY) , up 3.8% to $7.70.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.
TAGS: Investing | U.S. Equity | Healthcare | Drug Approvals | Stocks

More from Healthcare

UnitedHealth Group's Charts Continue to Point Higher

Bruce Kamich

Here's our next price target.

Here's My Risk and Reward Parameters for Vir Biotechnology

Bruce Kamich

Let's look over the charts and indicators.

Karuna Therapeutics Is Doing Important Research but Its Charts Are Weak

Bruce Kamich

The technical signals of the clinical-stage biotech company don't inspire confidence at this juncture.

Thrill Seekers Might Like 2 Downtrodden Stocks Insiders Are Buying

Bret Jensen

TherapeuticsMD and Spark Networks are beaten-down names with recent buying interest from insiders in common.

Market Participants Are Battling Omicron Pessimism

James "Rev Shark" DePorre

There are a number of issues to consider from a trading standpoint as we start the week.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight